| Literature DB >> 31216271 |
Amahyel M Gusi1, Wilson J Bertu1, M Jesús de Miguel2, Lucía Dieste-Pérez2, Henk L Smits3, Reuben A Ocholi1, José M Blasco2, Ignacio Moriyón4, Pilar M Muñoz2.
Abstract
BACKGROUND: Brucellosis is a world-wide extended zoonosis that causes a grave problem in developing economies. Animal vaccination and diagnosis are essential to control brucellosis, and the need for accurate but also simple and low-cost tests that can be implemented in low-infrastructure laboratories has been emphasized.Entities:
Mesh:
Substances:
Year: 2019 PMID: 31216271 PMCID: PMC6602290 DOI: 10.1371/journal.pntd.0007509
Source DB: PubMed Journal: PLoS Negl Trop Dis ISSN: 1935-2727
Costs and technical features of the tests used (RBT, LFA and ELISA).
| Features | RBT | LFA | ELISA | More advantageous tests according to this feature |
|---|---|---|---|---|
| Cost ($) of reagents or commercial kits per sample | 0.20–0.50 | 4–6 | 3–8 | RBT |
| Need for specific equipment | NO | NO | YES | RBT & LFA |
| Technical difficulty | Low | Low | Medium-High | RBT & LFA |
| Time required to process 100 to 1000 samples (h) | 0.3 to 3 | 0.3 to 3 | 3 to 4 | RBT & LFA |
| Automated reading of results | NO | NO | YES | ELISA |
| Need for serum pre-dilution | NO | NO | YES | RBT & LFA |
| Suitable for highly haemolyzed serum | NO | YES | YES | LFA & ELISA |
| Immunoglobulin detected | IgM and IgG | IgG | IgG | RBT |
| Useful for human diagnosis | YES | NO | NO | RBT |
1 Calculated as the division of the cost (approx.) of the material, reagents or commercial kits required by the number of samples tested.
2 Based on commercial kits prices found for different providers and countries.
3 Small common equipment like pipettes or washing devices not considered.
4 Absorbance microplate reader (cost from 5.000 to 10.000 $).
5 It depends on the conjugate used: the “in house” ELISA used in this work and most commercial ELISA kits detect IgG exclusively but ELISA tests detecting both IgM and IgG are also available
Diagnostic sensitivity (Dse) and specificity (Dsp) of LFA, RBT and iELISA assessed with sera from Brucella culture-positive animals and unvaccinated animals from brucellosis free areas, respectively.
| Number of positives / | Number of positives / Brucellosis-free sera tested | |||||
|---|---|---|---|---|---|---|
| LFA | RBT | iELISA | LFA | RBT | iELISA | |
| Cattle | 84/87 | 87/88 | 85/88 | 1/83 | 0/84 | 0/84 |
| Sheep | 94/100 | 92/100 | 100/100 | 0/101 | 0/101 | 0/101 |
| Goats | 44/46 | 45/46 | 46/46 | 2/52 | 0/52 | 0/52 |
| Swine | 36/39 | 36/39 | 39/39 | 0/46 | 0/46 | 0/46 |
1 DSe = 100 x Number of positives / Brucella culture-positive sera tested.
2 DSp = 100 x Number of negatives / Brucellosis-free sera tested.
3 One serum of the 88 culture-positive cattle failed to produce the control line in LFA.
4 One serum of the 84 brucellosis-free cattle failed to produce the control line in LFA.
Results of LFA, RBT and iELISA in sera from brucellosis-free vaccinated cattle.
| Number of positives / Number of sera tested (DSp) at the indicated bleeding times after vaccination with: | ||||
|---|---|---|---|---|
| S19 | RB51 | |||
| Subcutaneously | Conjunctivally | |||
| Test | 10 weeks | 21 weeks | 10 weeks | 9–18 weeks |
| LFA | 8/10 (20%) | 7/10 | 5/22 (77.3%) | 11/22 (50%) |
| RBT | 8/11 (27.3%) | 5/11 (54.5%) | 9/22 (59.1%) | 0/22 (100%) |
| iELISA | 9/11 (18.2%) | 7/11 (36.4%) | 6/22 (72.7%) | 17/22 (22.7%) |
1 One serum of the 11 animals failed to produce the control line in LFA.
Fig 1Apparent prevalence (percentage of positive animals) by RBT and LFA when testing cattle sera from a Brucella endemic area in Nigeria.